My Favorite Psychedelic Stocks: Part 1
Our resident Psychedelic Investor details five companies he thinks are in strong position to win the psychedelic medicine race.
compass pathways
DMT Vape Pen Patent Illustrates a Big Problem in the Psychedelics Industry
Problematic patents have serious implications for the entire psychedelics industry.
Psychedelic Business Spotlight – December 17
This week in psychedelic business news: Cybin steps closer to a new patent; MindMed appoints new CEO; MAPS and Wesana Health resume negotiations.
Compass Pathways Study Finds SSRI Drugs Did Not Impede Psilocybin’s Therapeutic Effect
Chief Medical Officer Guy Goodwin calls study “a strong signal that COMP360 psilocybin therapy could be an adjunctive treatment to SSRI antidepressant as well as a monotherapy.”
Psychedelic Business Spotlight: December 3
This week in psychedelic business news: MAPS pioneers new funding structure; FDA green lights a Cybin study for Covid-19 distress; Compass Pathways gets new majority stakeholder.
Compass Pathways Releases Promising New Data from Landmark Psilocybin Therapy Trial
Chief Medical Officer Dr. Guy Goodwin clarifies “COMP360 psilocybin therapy was generally well-tolerated” by patients with treatment-resistant depression, despite some adverse reactions from subjects in the study.
Psychedelic Business Spotlight: November 26
This week in psychedelic business news: Compass Pathways files another patent; Seelos Therapeutics raises big money; Cybin makes psychedelic therapy more accessible in NYC.
Psychedelic Business Spotlight: November 12
This week in psychedelic business news: two of the biggest players in the industry unveil big data; Numinus Wellness helps MAPS expand MDMA study; and Ketamine One announces IPO intention.
Largest Psilocybin Therapy Trial Ever Conducted Shows Depressive Symptoms Rapidly Reduce
“A single dose of psilocybin generated a rapid response that lasted up to 12 weeks,” explains principal investigator Dr. David J. Hellerstein, who was evaluating Compass Pathways’ novel drug formulation COMP360.
Psychedelic Business Spotlight: November 5
This week in psychedelic business news: DEA grants Cybin a Schedule I manufacturing license; PharmaTher partners with Revive Therapeutics on microneedle patch technology; Mydecine patents nanotechnology.
End of content
End of content